Samsung Bioepis Biosimilars 3 Types Achieve 9% Increase in European Sales in First Half of Year

European Marketing Partner Biogen Announces Q2 Earnings

[Asia Economy Reporter Cho Hyun-ui] Samsung Bioepis's three biosimilars (biopharmaceutical generics) achieved nearly $400 million in sales in Europe in the first half of this year, marking a 9% growth.

Samsung Bioepis announced this on the 23rd, citing the second-quarter earnings report of its European marketing partner, Biogen.

According to Biogen, Samsung Bioepis's three biosimilars for autoimmune disease treatment (Benepali, Flixabi, Imraldi) recorded sales of $390.4 million (approximately 469.7 billion KRW) in Europe during the first half of this year, a 9% increase compared to the same period last year.

However, due to the impact of COVID-19 and other factors, sales in the second quarter showed a decline. In the second quarter of this year, sales of the three biosimilars in Europe were $171.6 million (approximately 206.4 billion KRW), down 7% from the same period last year.

According to pharmaceutical market research firm IQVIA, compared to March, the market distribution volume in April fell by 13% each in the etanercept drug market, to which Benepali belongs, and the adalimumab drug market, to which Imraldi belongs.

Despite the second-quarter sales decline, the first-half performance rose compared to the same period last year thanks to strong first-quarter results. In the first quarter of this year, sales of the three biosimilars in Europe increased by 24% year-on-year to $218.8 million (approximately 267 billion KRW).

Samsung Bioepis stated that despite various external conditions, its market share in Europe continues to expand steadily. As of April, Benepali narrowed the gap with the original drug to less than 1% in the overall European market share. Imraldi holds over 30% market share in the Humira biosimilar market, where a total of five products are competing.

A Samsung Bioepis official said, "The European healthcare system is currently normalizing," adding, "Based on a stable product supply system, we will ensure that patients can receive their medications in a timely manner."

This content was produced with the assistance of AI translation services.